期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 60, 期 1, 页码 322-337出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01360
关键词
-
资金
- Alexander von Humboldt Foundation, Germany
- Council of Scientific and Industrial Research, New Delhi
The development of small molecule inhibitors targeting GPVI has promising therapeutic role, as they inhibit arterial thrombosis with limited risk of bleeding. Among the compounds showing in vivo antithrombotic activity, the most active compound 6b (ED50 = 28.36 mu mol/kg po in mice) showed improved inhibition for collagen (IC50 = 6.7 mu M), CRP-XL (IC50 = 53.5 mu M), and convuban (CVX) (IC50 = 5.7 /./M) mediated platelet aggregation as compared to losartan (LOS) (collagen, IC50 = 10.4 mu M; CRP-XL, IC50 = 158 /2M; CVX, IC50 = 11 1.4M) than any of its enantiomers S (6c) (collagen, IC50 = 25.3 mu M; CRP-XL, IC50 = 181.4 mu M; CVX, IC50 = 9 mu M) and R (6d) (collagen, IC50 = 126.3 mu M; CRP-XL, IC50 > 500 mu M, IC50 = 86.8 mu M). Compound 6b also inhibited platelet P-selectin expression and thus may diminish atherosclerosis. The molecular interactions of both enantiomers 6c and 6d at the GPVI receptor have been explained through docking studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据